


EUDRATEC® PEP

SWITCHING BIOLOGICS FROM PARENTERAL TO ORAL ADMINISTRATION



ORAL BIOAVAILABILITY OF LOW PERMEABLE DRUGS

EUDRATEC® PEP platform technology offers the combination of **synergistic modules for bioavailability enhancement** with a tailored release profile of your drug in the gastrointestinal tract (GI tract).



The combination and the type of these excipients allows you to design your own final dosage form for your specific poorly permeable drug.

WHAT MAKES EUDRATEC® PEP UNIQUE?



Tailored release profile – pH and time controlled



Enhanced bioavailability of low permeable drugs



Microparticles. Better distribution in GI tract



In vivo proven



Suitable for various drugs and dosage forms




Usage of conventional equipment



Patent protected

In vivo study with EUDRATEC® PEP: bioavailability enhancement of a peptidic drug



Our cutting-edge technology includes specific excipients to enhance the permeability of peptide drugs. The addition of a permeation enhancer, enzyme inhibitor and a mucocompatible excipient can be tailored to each specific drug.

The *in vivo* proven formulation concept showed in an animal trial with mini-piglets up to 7-fold improved bioavailability in comparison to the non-formulated peptide. A dose reduction of up to 80% is possible with the innovative technology EUDRATEC® PEP.

PATENT NO (WO, EP, US)	TITLE
WO2011103920 EP2538955 B1 US8765152	Pharmaceutical or nutraceutical formulation
WO2008012115 EP2046304 B1 US7871643	Pharmaceutical form with multilayer separating layer
WO2006061069 EP1824457 B1 US8568778	Multiparticulate form of administration, comprising nucleic acid -containing mucoadhesive active ingredients, and method for producing said form of administration
WO2006010453 EP1771157 B1 US8273375	Multiparticle pharmaceutical dosage form for low-soluble active substances and method for producing said pharmaceutical dosage form
WO2005007139 EP1643977 B1 US8734849	Multiparticle pharmaceutical dosage form containing mucoadhesively formulated peptide or protein active substances, and a method for producing said pharmaceutical dosage form

This information and all further technical advice are based on our present knowledge and experience. However, it implies no liability or other legal responsibility on our part, including with regard to existing third party intellectual property rights, especially patent rights. In particular, no warranty, whether express or implied, or guarantee of product properties in the legal sense is intended or implied. We reserve the right to make any changes according to technological progress or further developments. The customer is not released from the obligation to conduct careful inspection and testing of incoming goods. Performance of the product described herein should be verified by testing, which should be carried out only by qualified experts in the sole responsibility of a customer. Reference to trade names used by other companies is neither a recommendation, nor does it imply that similar products could not be used.

EUDRAGIT® - reg. trademark of Evonik Industries AG and its subsidiaries
 EUDRATEC® - reg. trademark of Evonik Industries AG and its subsidiaries

Evonik Nutrition & Care GmbH
Health Care Business Line
Pharma Polymers & Services

healthcare@evonik.com
www.evonik.com/oraldrugdelivery